Key Highlights

  • bioAffinity Technologies (NASDAQ:BIAF) was down 5.85% in premarket trading on October 9, 2026 on a listed price of USD 5.64, the October 8 close after an 8.44% fall that day.
  • The likely catalyst is an October 8 announcement of a roughly USD 4 million registered direct financing and concurrent private placement, with shares priced at USD 6.122, according to published company news.
  • The USD 6.122 Offer Price was about 8.5% above the USD 5.64 close, simple arithmetic, so the financing was priced at a premium to the closing price but the stock still fell.
  • The company said CyPath Lung sales grew more than 100% through the third quarter of 2026, yet full-year 2025 Revenue of USD 6.16 million was down from USD 9.36 million.

What Moved bioAffinity Shares

bioAffinity Technologies (NASDAQ:BIAF) was indicated down 5.85% in the October 9, 2026 premarket session on the screener, on a listed price of USD 5.64 and premarket Volume of 13,667 shares. The screener tags an other event. A published headline list shows that on October 8 the company announced a registered direct offering of about USD 4 million with shares sold at USD 6.122 and a concurrent private Placement priced at the market under Nasdaq rules, with WallachBeth Capital named in a related headline. The same list shows a Volatility halt that day and an 8.44% fall to the close. The details were taken from one data page and should be rechecked against the company filing.

Business, Sales Growth and Losses

bioAffinity develops non-invasive tests for early-stage lung cancer, mainly CyPath Lung, which analyzes sputum using flow cytometry and automated analysis, and it also runs laboratory services. The company said CyPath Lung sales grew more than 100% through the third quarter of 2026 compared with 2025, and it announced a Japan Patent allowance on October 8, a Hong Kong patent in September and a distribution Partnership with AvMEDICAL for veterans on September 30. Yet trailing revenue was about USD 5.90 million, down 23.2%, and the 2025 net loss was USD 14.91 million, up 64.9%. It regained Nasdaq compliance around September 9, 2026, after a period in which several volatility trading halts occurred.

Risks and What to Watch

Small diagnostic companies often finance repeatedly, and each registered direct offering adds shares at a price that may sit below later trading. bioAffinity Technologies (NASDAQ:BIAF) lost USD 14.91 million in 2025 on revenue of USD 6.16 million, so the USD 4 million raise covers only part of a year of losses. Regulatory, reimbursement and adoption risks apply to CyPath Lung, and a Market Value in the single-digit millions leaves the stock vulnerable to delisting rules and large swings in price. Investors should watch the closing and Warrant terms, third-quarter results, any further financing and Nasdaq compliance notices. A premarket decline on 13,667 shares can change at the open.

Where Things Stand

bioAffinity Technologies (NASDAQ:BIAF) is down in premarket, and the best-supported cause is the October 8 financing of about USD 4 million at USD 6.122 per share, reported in a published headline list that should be rechecked against the filing. The balance of evidence is that sales growth and patent progress are being offset by recurring dilution and losses far above revenue. The next checkpoints are the closing details, third-quarter results and any new financing or listing notices.